The present disclosure provides a novel fusion protein to overcome the current difficulties related to application of monoclonal antibodies in disease treatment and in other fields, particularly those requiring ADCC, e.g. for depletion of tumor cells, virally-infected cells, or immune-modulating cells, etc. One example of the fusion protein preferably comprising an extracellular domain of a high-affinity variant of human CD16A fused to an anti-CD3 antibody or its antigen-binding fragment thereof that specifically binds to an epitope on human CD3 or a fragment thereof.本揭示提供了一種新穎的融合蛋白，以克服現今單株抗體在疾病治療及其他領域應用中相關之困難，特別是在需要ADCC之領域中，例如去除腫瘤細胞、經病毒感染之細胞或免疫調節細胞等。融合蛋白之一個較佳實例包含了人類CD16A之高親和力變異體之胞外結構域與特異性結合至人類CD3上的抗原決定位或其片段的抗CD3抗體或其抗原結合片段的融合。
